BeiGene, Ltd. announced that marketing authorization applications for tislelizumab, submitted by Novartis, the license holder in Europe, have been validated for regulatory review by the European Medicines Agency for patients with advanced or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy and for patients with non-small cell lung cancers.
April 6, 2022
· 15 min read